Clinical trial
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
NCT03967223 is registered in ClinicalTrials.gov with USWM CT, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, Alone or in Combination With Other Agents, in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)
- Lead sponsor
- USWM CT, LLC
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- December 31, 2019
- Completion date
- July 31, 2028
- Enrollment
- 103 (actual)
- Sites
- 38
Conditions
As the registry lists them; a condition with its own page is linked.